CA2760527A1 - Procede de traitement d'une depression - Google Patents

Procede de traitement d'une depression Download PDF

Info

Publication number
CA2760527A1
CA2760527A1 CA2760527A CA2760527A CA2760527A1 CA 2760527 A1 CA2760527 A1 CA 2760527A1 CA 2760527 A CA2760527 A CA 2760527A CA 2760527 A CA2760527 A CA 2760527A CA 2760527 A1 CA2760527 A1 CA 2760527A1
Authority
CA
Canada
Prior art keywords
depression
viloxazine
activity
pharmaceutical agent
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2760527A
Other languages
English (en)
Inventor
Christopher D. Breder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Supernus Pharmaceuticals Inc
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of CA2760527A1 publication Critical patent/CA2760527A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2760527A 2009-04-30 2010-04-29 Procede de traitement d'une depression Abandoned CA2760527A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17408409P 2009-04-30 2009-04-30
US61/174,084 2009-04-30
PCT/US2010/032974 WO2010127120A1 (fr) 2009-04-30 2010-04-29 Procédé de traitement d'une dépression

Publications (1)

Publication Number Publication Date
CA2760527A1 true CA2760527A1 (fr) 2010-11-04

Family

ID=43032555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2760527A Abandoned CA2760527A1 (fr) 2009-04-30 2010-04-29 Procede de traitement d'une depression

Country Status (8)

Country Link
US (1) US20120115871A1 (fr)
EP (1) EP2424539A4 (fr)
JP (2) JP2012525426A (fr)
AU (1) AU2010242971A1 (fr)
CA (1) CA2760527A1 (fr)
CO (1) CO6470848A2 (fr)
MX (1) MX2011011579A (fr)
WO (1) WO2010127120A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341912B1 (fr) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Procédé de traitement de trouble déficitaire de l attention avec hyperactivité (adhd)
EP2812074B1 (fr) * 2012-02-08 2023-05-10 Supernus Pharmaceuticals, Inc. Formulations de liberation modifiée du viloxazine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260606A (en) * 1979-07-19 1981-04-07 A. H. Robins Company, Inc. 3-Methyleneazetidine derivatives
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (fr) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Agents a effet antidepresseur, comprenant du pramipexol et un autre antidepresseur
CA2431041A1 (fr) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company Nouvelles combinaisons medicamenteuses d'inhibiteurs de recaptage de la norepinehrine et d'agents neuroleptiques
JP5318757B2 (ja) * 2006-06-16 2013-10-16 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛の治療のための、組み合わされたセロトニンおよびノルエピネフリン再取り込み阻害を有する４−［２−（４−メチルフェニルスルファニル）−フェニル］ピペリジンの結晶形
EP2341912B1 (fr) * 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Procédé de traitement de trouble déficitaire de l attention avec hyperactivité (adhd)

Also Published As

Publication number Publication date
JP2014240417A (ja) 2014-12-25
EP2424539A4 (fr) 2012-09-19
AU2010242971A1 (en) 2011-11-24
JP2012525426A (ja) 2012-10-22
MX2011011579A (es) 2012-01-27
CO6470848A2 (es) 2012-06-29
WO2010127120A1 (fr) 2010-11-04
US20120115871A1 (en) 2012-05-10
EP2424539A1 (fr) 2012-03-07

Similar Documents

Publication Publication Date Title
US11458143B2 (en) Method of treatment of attention deficit/hyperactivity disorder (ADHD)
SK286864B6 (sk) Použitie opticky čistého (S,S) reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu fibromyalgie alebo iných somatoformných porúch
Buck et al. L-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective
WO2006106308A1 (fr) Utilisation therapeutique du nefopam et analogues de celui-ci
AU2006231752B2 (en) Preventive or remedy for depression or anxiety neurosis
KR20010108368A (ko) 항우울제로서 특정 친화도의 ｎｍｄａ 길항제의 용도
Bourin et al. Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity.
KR20050049476A (ko) 홍조를 치료하기 위한 레복세틴의 용도
CA2760527A1 (fr) Procede de traitement d'une depression
Pinder Adrenoreceptor interactions of the enantiomers and metabolites of mianserin: are they responsible for the antidepressant effect?
Chaturvedi et al. Effect of NMDA receptor antagonists in forced swimming test and its modification by antidepressants
US11191758B2 (en) Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
PL197981B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
Chojnacka-Wójcik et al. Involvement of 5-hydroxytryptamine-1C (5-HT1C) receptors in m-chlorophenylpiperazine-induced antinociception
Stein et al. Serotonergic responsivity in trichotillomania
MARSHALL Wong et al.
Leatherman et al. Effects of desipramine on 5-HT function in depressed patients and healthy subjects
Leatherman et al. 5-HT3 receptors and the nausea and prolactin responses to clomipramine challenge
PL197982B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
PL197984B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160429